NASDAQ$JANX
Janux Therapeutics Inc · Q1 2023 earnings
Q1 2023 earnings · · Investor relations
Briefing
Reported financial results for the first quarter ended March 31, 2023 and provided a business update.
Janux Therapeutics reported first quarter 2023 financial results, including cash and cash equivalents and short-term investments of $316.9 million. The company's research and development expenses were $15.9 million, and general and administrative expenses were $6.5 million, resulting in a net loss of $17.5 million.
- First patient dosed with EGFR-TRACTr (JANX008) in first-in-human Phase 1 clinical trial in patients with solid tumors.
- Interim clinical update from Phase 1 trial of JANX007 expected in 2H 2023.
- Cash and cash equivalents and short-term investments totaled $316.9 million at the end of the first quarter 2023.
- PSMA-TRACTr (JANX007) continues to enroll in first-in-human Phase 1 clinical trial in mCRPC.
Headline financials
Revenue & EPS history
Janux · Revenue · Quarterly
$2.05M
Revenue by segment
Janux · $2.05M total across 1 segment · Q1 2023
- Collaboration revenue$2.05M+28.9%100.0%
Forward guidance
Janux anticipates providing an interim clinical update from the PSMA-TRACTr (JANX007) trial in the second half of 2023. In addition, Janux expects to select a development candidate for its TROP2-TRACTr in 2023.
Tailwinds
- PSMA-TRACTr (JANX007) continues to enroll in first-in-human Phase 1 clinical trial in mCRPC.
- First patient dosed with EGFR-TRACTr program (JANX008) in first-in-human Phase 1 clinical trial in patients with solid tumors.
- PD-L1xCD28 TRACIr (JANX009) on-track for an IND submission in 2023.
- TROP2-TRACTr evaluations to support development candidate selection are ongoing.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2023
+0.6%
Avg return
Earnings day
-1.5%
Avg return
5 days after
-5.5%
Avg return
30 days after
42%
8 / 19 earnings
Positive
+14.6%
Q3 2022
Best reaction
-11.0%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.6% | -1.4% | -8.8% | |
| Q4 2025 | -1.4% | +4.0% | -4.5% | |
| Q3 2025 | +3.9% | +4.8% | -40.1% | |
| Q1 2025 | -0.8% | +3.8% | -2.8% | |
| Q4 2024 | +2.7% | -1.6% | -9.1% | |
| Q3 2024 | -1.9% | -2.9% | +17.6% | |
| Q2 2024 | -1.1% | -0.8% | +11.8% | |
| Q1 2024 | -11.0% | -21.3% | -31.5% | |
| Q4 2023 | -1.6% | -1.7% | -13.5% | |
| Q3 2023 | +5.9% | -3.4% | +50.7% | |
| Q2 2023 | +5.1% | +4.3% | -11.6% | |
| Q1 2023 | +1.1% | -7.0% | -3.5% | |
| Q4 2022 | -2.5% | -4.7% | -4.9% | |
| Q3 2022 | +14.6% | +5.3% | -9.8% | |
| Q2 2022 | +1.0% | -4.9% | -3.2% | |
| Q1 2022 | +6.1% | +13.7% | +10.0% | |
| Q4 2021 | -6.0% | -3.5% | -17.1% | |
| Q3 2021 | -1.6% | -7.4% | -23.9% | |
| Q2 2021 | -1.0% | -3.8% | -9.9% | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro